Fisher Asset Management LLC Grows Stock Position in United Therapeutics Corporation $UTHR

Fisher Asset Management LLC grew its holdings in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 24.5% in the 4th quarter, Holdings Channel.com reports. The firm owned 29,357 shares of the biotechnology company’s stock after purchasing an additional 5,777 shares during the quarter. Fisher Asset Management LLC’s holdings in United Therapeutics were worth $14,304,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the business. Darwin Global Management Ltd. purchased a new stake in shares of United Therapeutics during the 3rd quarter valued at about $317,617,000. Baillie Gifford & Co. purchased a new stake in shares of United Therapeutics during the 4th quarter valued at about $157,390,000. UBS Group AG increased its position in shares of United Therapeutics by 45.3% during the 4th quarter. UBS Group AG now owns 225,849 shares of the biotechnology company’s stock valued at $110,045,000 after purchasing an additional 70,445 shares during the last quarter. Soleus Capital Management L.P. increased its position in shares of United Therapeutics by 35.0% during the 2nd quarter. Soleus Capital Management L.P. now owns 209,794 shares of the biotechnology company’s stock valued at $60,284,000 after purchasing an additional 54,400 shares during the last quarter. Finally, Legal & General Group Plc increased its position in shares of United Therapeutics by 0.6% during the 3rd quarter. Legal & General Group Plc now owns 199,656 shares of the biotechnology company’s stock valued at $83,698,000 after purchasing an additional 1,137 shares during the last quarter. Hedge funds and other institutional investors own 94.08% of the company’s stock.

United Therapeutics Stock Down 1.3%

Shares of United Therapeutics stock opened at $570.75 on Thursday. The firm has a market cap of $24.23 billion, a price-to-earnings ratio of 21.07, a PEG ratio of 1.87 and a beta of 0.60. The business has a 50-day moving average price of $565.54 and a 200-day moving average price of $514.75. United Therapeutics Corporation has a twelve month low of $272.12 and a twelve month high of $609.35.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The firm had revenue of $781.50 million for the quarter, compared to analysts’ expectations of $797.40 million. During the same quarter in the previous year, the business earned $6.63 EPS. The company’s revenue for the quarter was down 1.6% on a year-over-year basis. On average, equities analysts expect that United Therapeutics Corporation will post 27.07 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on UTHR shares. TD Cowen reiterated a “buy” rating on shares of United Therapeutics in a research note on Thursday, May 21st. UBS Group boosted their price objective on United Therapeutics from $655.00 to $705.00 and gave the company a “buy” rating in a research note on Thursday, March 5th. Wells Fargo & Company upgraded United Therapeutics from an “equal weight” rating to an “overweight” rating and boosted their price objective for the company from $575.00 to $735.00 in a research note on Thursday, May 7th. Raymond James Financial started coverage on United Therapeutics in a research note on Friday, April 10th. They set an “outperform” rating and a $700.00 price objective for the company. Finally, HC Wainwright boosted their price objective on United Therapeutics from $600.00 to $660.00 and gave the company a “buy” rating in a research note on Tuesday, March 31st. Eleven analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $619.42.

Insider Buying and Selling

In other news, CFO James Edgemond sold 10,000 shares of the stock in a transaction that occurred on Monday, March 23rd. The stock was sold at an average price of $527.48, for a total transaction of $5,274,800.00. Following the completion of the transaction, the chief financial officer directly owned 18,876 shares in the company, valued at approximately $9,956,712.48. This represents a 34.63% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders sold 581,973 shares of company stock worth $325,968,044 over the last three months. 8.60% of the stock is currently owned by corporate insiders.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.